Mosi Eye Drops 5 ml

babies: safe. lactating mothers: it is probably unsafe to use during breastfeeding. limited human data suggests that the drug may pass into the breastmilk and harm the baby.
please consult your doctor. pregnancy: it is unsafe to use during pregnancy. although there are limited studies in humans, animal studies have shown harmful effects on the developing baby.
please consult your doctor. driving: it may cause side effects that could affect your ability to drive. alcohol: no interaction found. liver: no interaction found. kidney: no interaction found..

Eye discomfort Dry eye Burning sensation.

MOSI eyedrop is an antibiotic. it works by stopping the bacterial enzyme which thereby, prevents the bacteria from dividing and repairing..

If you miss a dose of MOSI, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• the MOSI eye drop is an antibiotic used to treat eye bacterial infections. • do not skip any doses and finish the complete course of treatment even if you feel better.
• after instilling the medication, immediately apply pressure on the corner of the eye for about 1 minute. • before delivering another dose in the same eye, wait for at least 5-10 minutes to avoid dilution.
• it may cause short-term blurring of vision when first used. use caution before driving or using machines.
• should not wear contact lenses until your infection clears up. • make sure to use it within four weeks of opening the medication..

contraindicated • mosi + bepridil: concurrent use may increase the risk of qt-interval prolongation • mosi + cisapride: concurrent use may increase the risk of qt-interval prolongation • mosi + dronedarone: concurrent use may increase the risk of qt-interval prolongation • mosi + pimozide: concurrent use may increase the risk of qt-interval prolongation • mosi + piperaquine: concurrent use may increase the risk of qt-interval prolongation • mosi + thioridazine: concurrent use may increase the risk of qt-interval prolongation major • mosi + acarbose: concurrent use may increase the risk of hypoglycaemia or hyperglycemia • mosi + rasagiline: concurrent use may result in increased rasagiline exposure • mosi + tamoxifen: concurrent use may increase the risk of qt-interval prolongation.